 Ajaypal Singh
Concepts (475)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia | 47 | 2017 | 87 | 14.230 |
Why?
| | Hematinics | 37 | 2017 | 40 | 12.460 |
Why?
| | Erythropoietin | 35 | 2015 | 46 | 10.000 |
Why?
| | Kidney Failure, Chronic | 30 | 2017 | 152 | 9.060 |
Why?
| | Kidney Diseases | 25 | 2017 | 132 | 8.700 |
Why?
| | Hemoglobins | 34 | 2017 | 75 | 8.010 |
Why?
| | Renal Insufficiency, Chronic | 21 | 2017 | 74 | 6.600 |
Why?
| | Renal Dialysis | 29 | 2017 | 95 | 6.530 |
Why?
| | Tomography, X-Ray Computed | 26 | 2019 | 781 | 5.800 |
Why?
| | Blast Injuries | 5 | 2016 | 7 | 3.050 |
Why?
| | Kidney | 10 | 2016 | 174 | 2.920 |
Why?
| | Humans | 132 | 2019 | 25275 | 2.890 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2013 | 282 | 2.310 |
Why?
| | Terrorism | 5 | 2016 | 14 | 1.930 |
Why?
| | Middle Aged | 58 | 2018 | 9439 | 1.880 |
Why?
| | Recombinant Proteins | 20 | 2013 | 291 | 1.830 |
Why?
| | Anemia, Iron-Deficiency | 4 | 2015 | 5 | 1.770 |
Why?
| | Male | 69 | 2018 | 14662 | 1.750 |
Why?
| | Female | 68 | 2019 | 14955 | 1.640 |
Why?
| | Foreign Bodies | 3 | 2015 | 19 | 1.600 |
Why?
| | Mass Screening | 3 | 2014 | 165 | 1.550 |
Why?
| | Magnetic Resonance Imaging | 7 | 2018 | 1021 | 1.540 |
Why?
| | Heart Failure | 9 | 2017 | 176 | 1.510 |
Why?
| | Adult | 38 | 2018 | 8233 | 1.490 |
Why?
| | Chronic Disease | 16 | 2010 | 458 | 1.460 |
Why?
| | Aged | 46 | 2019 | 8370 | 1.440 |
Why?
| | Nephrology | 3 | 2016 | 13 | 1.370 |
Why?
| | Cardiovascular Diseases | 11 | 2017 | 293 | 1.360 |
Why?
| | Lupus Nephritis | 4 | 2006 | 29 | 1.350 |
Why?
| | Diabetes Mellitus, Type 2 | 10 | 2017 | 180 | 1.340 |
Why?
| | Biopsy, Needle | 3 | 2012 | 115 | 1.320 |
Why?
| | Multiple Trauma | 4 | 2016 | 5 | 1.290 |
Why?
| | Diabetic Nephropathies | 5 | 2015 | 37 | 1.270 |
Why?
| | Kidney Transplantation | 5 | 2009 | 121 | 1.220 |
Why?
| | Risk Factors | 21 | 2015 | 2162 | 1.210 |
Why?
| | Bone Diseases, Metabolic | 3 | 2016 | 15 | 1.120 |
Why?
| | Liver Transplantation | 3 | 2015 | 90 | 1.110 |
Why?
| | Vitamin D | 3 | 2013 | 17 | 1.090 |
Why?
| | Colitis | 3 | 2005 | 28 | 1.060 |
Why?
| | Prevalence | 10 | 2016 | 473 | 1.030 |
Why?
| | United States Food and Drug Administration | 3 | 2010 | 70 | 0.990 |
Why?
| | Prognosis | 9 | 2017 | 826 | 0.990 |
Why?
| | Practice Guidelines as Topic | 8 | 2012 | 330 | 0.980 |
Why?
| | Treatment Outcome | 20 | 2017 | 3134 | 0.930 |
Why?
| | Glomerular Filtration Rate | 8 | 2016 | 60 | 0.930 |
Why?
| | Hypertension | 5 | 2017 | 209 | 0.900 |
Why?
| | Acute Kidney Injury | 3 | 2014 | 40 | 0.890 |
Why?
| | Iron | 3 | 2015 | 16 | 0.890 |
Why?
| | Fasciitis, Necrotizing | 1 | 2018 | 2 | 0.880 |
Why?
| | Ferric Compounds | 4 | 2015 | 6 | 0.850 |
Why?
| | Lower Extremity | 1 | 2018 | 35 | 0.850 |
Why?
| | Marijuana Smoking | 1 | 2017 | 4 | 0.820 |
Why?
| | Head Injuries, Penetrating | 1 | 2017 | 1 | 0.810 |
Why?
| | Boston | 6 | 2016 | 21 | 0.810 |
Why?
| | Wounds, Gunshot | 1 | 2017 | 5 | 0.810 |
Why?
| | Retrospective Studies | 15 | 2018 | 2518 | 0.810 |
Why?
| | Blood Glucose | 1 | 2017 | 109 | 0.800 |
Why?
| | Ferritins | 5 | 2017 | 9 | 0.790 |
Why?
| | Pathology | 1 | 2016 | 4 | 0.770 |
Why?
| | Cytokines | 2 | 2008 | 331 | 0.760 |
Why?
| | Evidence-Based Medicine | 4 | 2010 | 194 | 0.750 |
Why?
| | Abdominal Injuries | 1 | 2015 | 5 | 0.740 |
Why?
| | Biliary Fistula | 2 | 2006 | 5 | 0.740 |
Why?
| | Renal Replacement Therapy | 2 | 2015 | 18 | 0.740 |
Why?
| | Proteinuria | 4 | 2013 | 104 | 0.740 |
Why?
| | Triage | 1 | 2016 | 23 | 0.740 |
Why?
| | Risk Assessment | 10 | 2017 | 664 | 0.740 |
Why?
| | Pelvis | 1 | 2015 | 22 | 0.730 |
Why?
| | Certification | 1 | 2016 | 51 | 0.730 |
Why?
| | Saudi Arabia | 6 | 2016 | 7 | 0.720 |
Why?
| | Neck Injuries | 1 | 2015 | 4 | 0.720 |
Why?
| | Craniocerebral Trauma | 1 | 2015 | 10 | 0.720 |
Why?
| | Medicare | 4 | 2010 | 71 | 0.720 |
Why?
| | Adolescent | 12 | 2016 | 2270 | 0.720 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 65 | 0.710 |
Why?
| | Consanguinity | 2 | 2014 | 3 | 0.700 |
Why?
| | Contrast Media | 5 | 2015 | 139 | 0.690 |
Why?
| | Radiography, Interventional | 3 | 2012 | 25 | 0.680 |
Why?
| | United States | 11 | 2017 | 1960 | 0.680 |
Why?
| | Diagnosis, Differential | 10 | 2019 | 433 | 0.680 |
Why?
| | Hypertension, Renal | 1 | 2014 | 5 | 0.670 |
Why?
| | Societies, Medical | 1 | 2016 | 170 | 0.670 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 87 | 0.660 |
Why?
| | Ventricular Fibrillation | 1 | 2014 | 23 | 0.650 |
Why?
| | Death, Sudden, Cardiac | 1 | 2014 | 23 | 0.650 |
Why?
| | Cost of Illness | 1 | 2014 | 49 | 0.640 |
Why?
| | Heart Arrest | 1 | 2014 | 44 | 0.640 |
Why?
| | Acute Disease | 6 | 2017 | 253 | 0.640 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 12 | 0.630 |
Why?
| | Pediatrics | 1 | 2013 | 50 | 0.610 |
Why?
| | Research Design | 4 | 2008 | 180 | 0.600 |
Why?
| | Biomedical Research | 1 | 2013 | 75 | 0.590 |
Why?
| | Kidney Tubules | 2 | 2009 | 10 | 0.590 |
Why?
| | Platelet Activation | 1 | 2012 | 3 | 0.580 |
Why?
| | Tissue Donors | 3 | 2015 | 54 | 0.580 |
Why?
| | Splenic Diseases | 1 | 2012 | 3 | 0.580 |
Why?
| | Disease Outbreaks | 1 | 2012 | 88 | 0.570 |
Why?
| | Blood Platelets | 1 | 2012 | 51 | 0.570 |
Why?
| | Spleen | 1 | 2012 | 52 | 0.570 |
Why?
| | Organotechnetium Compounds | 2 | 2008 | 11 | 0.570 |
Why?
| | Abdomen, Acute | 3 | 2008 | 5 | 0.560 |
Why?
| | Ciprofloxacin | 2 | 2008 | 33 | 0.560 |
Why?
| | Fanconi Syndrome | 1 | 2011 | 1 | 0.560 |
Why?
| | Injections, Subcutaneous | 3 | 2010 | 37 | 0.560 |
Why?
| | Red-Cell Aplasia, Pure | 2 | 2008 | 2 | 0.560 |
Why?
| | Child | 7 | 2016 | 1315 | 0.560 |
Why?
| | Appendicitis | 2 | 2008 | 10 | 0.550 |
Why?
| | Multiple Myeloma | 1 | 2011 | 26 | 0.550 |
Why?
| | Mass Casualty Incidents | 3 | 2016 | 6 | 0.550 |
Why?
| | Surgery, Computer-Assisted | 1 | 2012 | 54 | 0.540 |
Why?
| | Bombs | 3 | 2015 | 3 | 0.530 |
Why?
| | Liver | 2 | 2015 | 194 | 0.520 |
Why?
| | Preoperative Care | 4 | 2015 | 128 | 0.510 |
Why?
| | Biliary Tract Diseases | 1 | 2010 | 5 | 0.510 |
Why?
| | Stroke | 6 | 2017 | 305 | 0.500 |
Why?
| | Reimbursement Mechanisms | 1 | 2010 | 13 | 0.500 |
Why?
| | Drug Approval | 1 | 2010 | 33 | 0.500 |
Why?
| | Vascular Diseases | 1 | 2010 | 41 | 0.490 |
Why?
| | Liver Diseases | 1 | 2010 | 36 | 0.490 |
Why?
| | Calcium Compounds | 1 | 2009 | 2 | 0.470 |
Why?
| | Early Diagnosis | 4 | 2014 | 63 | 0.470 |
Why?
| | Minerals | 1 | 2009 | 7 | 0.470 |
Why?
| | Inflammation | 2 | 2008 | 284 | 0.470 |
Why?
| | Aged, 80 and over | 11 | 2017 | 4259 | 0.460 |
Why?
| | Medicine, Traditional | 1 | 2008 | 1 | 0.460 |
Why?
| | Predictive Value of Tests | 7 | 2016 | 535 | 0.460 |
Why?
| | Bone Density Conservation Agents | 1 | 2009 | 11 | 0.460 |
Why?
| | Bone Diseases, Infectious | 1 | 2008 | 3 | 0.460 |
Why?
| | Needles | 1 | 2008 | 11 | 0.460 |
Why?
| | Abdominal Muscles | 1 | 2008 | 5 | 0.450 |
Why?
| | Muscle Neoplasms | 1 | 2008 | 5 | 0.450 |
Why?
| | Phosphates | 1 | 2008 | 14 | 0.450 |
Why?
| | Cost Savings | 1 | 2008 | 32 | 0.450 |
Why?
| | Pelvic Pain | 1 | 2008 | 11 | 0.450 |
Why?
| | Immunologic Factors | 1 | 2008 | 36 | 0.440 |
Why?
| | Acute Coronary Syndrome | 1 | 2008 | 11 | 0.440 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 89 | 0.440 |
Why?
| | Bacterial Infections | 1 | 2008 | 64 | 0.440 |
Why?
| | Kidney Glomerulus | 1 | 2009 | 82 | 0.440 |
Why?
| | India | 3 | 2014 | 20 | 0.440 |
Why?
| | Hospital Mortality | 2 | 2014 | 131 | 0.440 |
Why?
| | Nephritis, Interstitial | 2 | 2008 | 6 | 0.440 |
Why?
| | Bone and Bones | 1 | 2009 | 91 | 0.440 |
Why?
| | Calculi | 1 | 2008 | 3 | 0.440 |
Why?
| | Abdominal Abscess | 1 | 2008 | 5 | 0.440 |
Why?
| | Endothelium, Vascular | 1 | 2008 | 70 | 0.440 |
Why?
| | Appendectomy | 1 | 2008 | 10 | 0.440 |
Why?
| | Endoscopy | 1 | 2010 | 156 | 0.430 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2013 | 492 | 0.430 |
Why?
| | Multicenter Studies as Topic | 2 | 2007 | 61 | 0.430 |
Why?
| | Outcome Assessment (Health Care) | 2 | 2010 | 279 | 0.430 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2009 | 82 | 0.430 |
Why?
| | Carcinoma, Renal Cell | 1 | 2008 | 74 | 0.420 |
Why?
| | Myocardial Infarction | 3 | 2017 | 163 | 0.410 |
Why?
| | Pancreatic Fistula | 1 | 2006 | 2 | 0.400 |
Why?
| | Ascites | 1 | 2006 | 5 | 0.400 |
Why?
| | Neoplasms | 2 | 2009 | 221 | 0.400 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 32 | 0.400 |
Why?
| | Diabetes Complications | 1 | 2007 | 56 | 0.390 |
Why?
| | Algorithms | 4 | 2016 | 377 | 0.390 |
Why?
| | Tissue and Organ Procurement | 1 | 2006 | 30 | 0.380 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 364 | 0.380 |
Why?
| | Penile Neoplasms | 1 | 2005 | 4 | 0.370 |
Why?
| | Hernia, Abdominal | 1 | 2005 | 2 | 0.360 |
Why?
| | Iron Compounds | 1 | 2005 | 2 | 0.360 |
Why?
| | Metabolic Diseases | 1 | 2005 | 14 | 0.350 |
Why?
| | Cohort Studies | 7 | 2014 | 1512 | 0.340 |
Why?
| | Cross-Sectional Studies | 5 | 2013 | 739 | 0.340 |
Why?
| | Infertility | 1 | 2004 | 2 | 0.340 |
Why?
| | Fertility | 1 | 2004 | 9 | 0.340 |
Why?
| | Colonic Diseases | 1 | 2004 | 14 | 0.340 |
Why?
| | Testis | 1 | 2004 | 11 | 0.340 |
Why?
| | Intestinal Fistula | 1 | 2004 | 9 | 0.340 |
Why?
| | Gallbladder Diseases | 1 | 2004 | 7 | 0.340 |
Why?
| | Mesenteric Vascular Occlusion | 1 | 2004 | 4 | 0.340 |
Why?
| | Infarction | 1 | 2004 | 6 | 0.330 |
Why?
| | Pancreaticoduodenectomy | 1 | 2004 | 36 | 0.330 |
Why?
| | Cyclophosphamide | 1 | 2004 | 54 | 0.330 |
Why?
| | Omentum | 1 | 2004 | 9 | 0.330 |
Why?
| | Severity of Illness Index | 5 | 2012 | 1094 | 0.330 |
Why?
| | Glomerulonephritis | 1 | 2004 | 25 | 0.330 |
Why?
| | Immunosuppressive Agents | 2 | 2009 | 145 | 0.330 |
Why?
| | Biopsy | 4 | 2011 | 256 | 0.330 |
Why?
| | Immunosuppression | 1 | 2004 | 39 | 0.330 |
Why?
| | Ovary | 1 | 2004 | 26 | 0.330 |
Why?
| | Radiographic Image Enhancement | 1 | 2004 | 15 | 0.330 |
Why?
| | Granuloma | 1 | 2003 | 12 | 0.330 |
Why?
| | Ibuprofen | 1 | 2003 | 10 | 0.330 |
Why?
| | Cholelithiasis | 1 | 2003 | 10 | 0.320 |
Why?
| | Gastric Outlet Obstruction | 1 | 2003 | 5 | 0.320 |
Why?
| | Young Adult | 5 | 2017 | 1782 | 0.320 |
Why?
| | Comorbidity | 3 | 2013 | 471 | 0.310 |
Why?
| | Incidence | 3 | 2017 | 673 | 0.310 |
Why?
| | Nurse's Role | 1 | 2005 | 132 | 0.310 |
Why?
| | Hyperparathyroidism, Secondary | 2 | 2016 | 4 | 0.310 |
Why?
| | Patient Education as Topic | 3 | 2010 | 179 | 0.300 |
Why?
| | Survival Analysis | 3 | 2009 | 358 | 0.300 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2004 | 83 | 0.290 |
Why?
| | Survival Rate | 3 | 2014 | 386 | 0.280 |
Why?
| | Injections, Intravenous | 4 | 2008 | 53 | 0.270 |
Why?
| | Confidence Intervals | 3 | 2012 | 103 | 0.260 |
Why?
| | Models, Biological | 1 | 2003 | 417 | 0.260 |
Why?
| | Disease Progression | 4 | 2017 | 723 | 0.250 |
Why?
| | Child, Preschool | 4 | 2016 | 712 | 0.250 |
Why?
| | Prospective Studies | 6 | 2016 | 1448 | 0.250 |
Why?
| | Hospitalization | 4 | 2017 | 259 | 0.240 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2002 | 165 | 0.240 |
Why?
| | Drainage | 2 | 2012 | 50 | 0.240 |
Why?
| | Catheterization | 2 | 2012 | 59 | 0.240 |
Why?
| | Deglutition Disorders | 1 | 2019 | 42 | 0.240 |
Why?
| | Myositis | 1 | 2019 | 21 | 0.240 |
Why?
| | C-Reactive Protein | 2 | 2017 | 122 | 0.240 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 45 | 0.230 |
Why?
| | Running | 2 | 2016 | 19 | 0.230 |
Why?
| | Ultrasonography, Interventional | 2 | 2012 | 59 | 0.230 |
Why?
| | Ultrasonography | 2 | 2018 | 163 | 0.230 |
Why?
| | Fractures, Closed | 1 | 2018 | 2 | 0.220 |
Why?
| | Leiomyoma | 2 | 2008 | 8 | 0.220 |
Why?
| | Foot Injuries | 1 | 2018 | 2 | 0.220 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 61 | 0.220 |
Why?
| | Ankle Injuries | 1 | 2018 | 10 | 0.220 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2010 | 189 | 0.220 |
Why?
| | Drug Costs | 2 | 2008 | 16 | 0.220 |
Why?
| | Up-Regulation | 2 | 2010 | 186 | 0.220 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2017 | 1 | 0.220 |
Why?
| | Continental Population Groups | 2 | 2009 | 94 | 0.210 |
Why?
| | Patient Selection | 2 | 2010 | 225 | 0.210 |
Why?
| | Quality of Life | 4 | 2017 | 508 | 0.200 |
Why?
| | Glasgow Coma Scale | 1 | 2017 | 17 | 0.200 |
Why?
| | Double-Blind Method | 6 | 2017 | 464 | 0.200 |
Why?
| | Antihypertensive Agents | 1 | 2017 | 62 | 0.200 |
Why?
| | Public Health | 1 | 2017 | 45 | 0.200 |
Why?
| | Follow-Up Studies | 6 | 2014 | 1745 | 0.200 |
Why?
| | Executive Function | 2 | 2014 | 81 | 0.200 |
Why?
| | Blood Pressure | 1 | 2017 | 191 | 0.200 |
Why?
| | Sensitivity and Specificity | 5 | 2018 | 562 | 0.190 |
Why?
| | International Cooperation | 1 | 2016 | 36 | 0.190 |
Why?
| | Explosions | 1 | 2016 | 1 | 0.190 |
Why?
| | Pilot Projects | 3 | 2017 | 371 | 0.190 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 3 | 0.190 |
Why?
| | Age Factors | 3 | 2014 | 773 | 0.190 |
Why?
| | Drug Monitoring | 2 | 2006 | 25 | 0.190 |
Why?
| | Muscle, Skeletal | 1 | 2019 | 323 | 0.190 |
Why?
| | Program Development | 1 | 2016 | 67 | 0.180 |
Why?
| | Diphosphates | 1 | 2015 | 1 | 0.180 |
Why?
| | Dialysis Solutions | 1 | 2015 | 5 | 0.180 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 7 | 0.180 |
Why?
| | Trauma Centers | 1 | 2015 | 9 | 0.180 |
Why?
| | Radiography | 1 | 2018 | 672 | 0.180 |
Why?
| | Radiopharmaceuticals | 2 | 2007 | 55 | 0.180 |
Why?
| | Risk Reduction Behavior | 3 | 2011 | 44 | 0.180 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2014 | 13 | 0.170 |
Why?
| | Wounds, Penetrating | 1 | 2014 | 8 | 0.170 |
Why?
| | Cognition Disorders | 2 | 2014 | 1035 | 0.170 |
Why?
| | Curriculum | 1 | 2016 | 129 | 0.170 |
Why?
| | Corneal Opacity | 1 | 2014 | 3 | 0.170 |
Why?
| | Acidosis, Renal Tubular | 1 | 2014 | 2 | 0.170 |
Why?
| | Sex Factors | 2 | 2013 | 421 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2014 | 10 | 0.160 |
Why?
| | Electric Countershock | 1 | 2014 | 20 | 0.160 |
Why?
| | Kidney Function Tests | 2 | 2017 | 26 | 0.160 |
Why?
| | Pedigree | 1 | 2013 | 71 | 0.160 |
Why?
| | Defibrillators, Implantable | 1 | 2014 | 19 | 0.160 |
Why?
| | Blood Viscosity | 1 | 2013 | 10 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 3 | 2012 | 185 | 0.160 |
Why?
| | Coronary Angiography | 1 | 2014 | 84 | 0.160 |
Why?
| | Time Factors | 3 | 2010 | 1620 | 0.160 |
Why?
| | Critical Care | 1 | 2016 | 183 | 0.160 |
Why?
| | Chi-Square Distribution | 2 | 2010 | 176 | 0.160 |
Why?
| | Sex Distribution | 1 | 2013 | 77 | 0.150 |
Why?
| | Middle East | 1 | 2012 | 5 | 0.150 |
Why?
| | Age Distribution | 1 | 2013 | 109 | 0.150 |
Why?
| | Calcinosis | 2 | 2014 | 46 | 0.150 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 1 | 0.150 |
Why?
| | P-Selectin | 1 | 2012 | 3 | 0.150 |
Why?
| | Electrocardiography | 1 | 2014 | 197 | 0.150 |
Why?
| | Regression Analysis | 2 | 2012 | 301 | 0.150 |
Why?
| | CD40 Ligand | 1 | 2012 | 9 | 0.150 |
Why?
| | Splenic Artery | 1 | 2012 | 1 | 0.150 |
Why?
| | Sclerosing Solutions | 1 | 2012 | 3 | 0.150 |
Why?
| | Sclerotherapy | 1 | 2012 | 2 | 0.150 |
Why?
| | Pneumothorax | 1 | 2012 | 11 | 0.140 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2012 | 8 | 0.140 |
Why?
| | Aneurysm, False | 1 | 2012 | 13 | 0.140 |
Why?
| | Postoperative Hemorrhage | 1 | 2012 | 23 | 0.140 |
Why?
| | Radionuclide Imaging | 2 | 2008 | 62 | 0.140 |
Why?
| | Population Surveillance | 1 | 2012 | 118 | 0.140 |
Why?
| | Osteomyelitis | 2 | 2008 | 23 | 0.140 |
Why?
| | Catheter Ablation | 1 | 2012 | 44 | 0.140 |
Why?
| | Thrombosis | 2 | 2017 | 61 | 0.140 |
Why?
| | Microscopy, Electron | 1 | 2011 | 94 | 0.140 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 42 | 0.140 |
Why?
| | Risk | 2 | 2010 | 204 | 0.140 |
Why?
| | Drug Therapy, Combination | 3 | 2008 | 247 | 0.130 |
Why?
| | Erythropoiesis | 1 | 2010 | 3 | 0.130 |
Why?
| | Embolization, Therapeutic | 1 | 2012 | 71 | 0.130 |
Why?
| | Hepatectomy | 1 | 2011 | 53 | 0.130 |
Why?
| | Multivariate Analysis | 4 | 2015 | 347 | 0.130 |
Why?
| | Iron, Dietary | 1 | 2010 | 1 | 0.130 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 1 | 0.130 |
Why?
| | Hepcidins | 1 | 2010 | 1 | 0.130 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2010 | 4 | 0.130 |
Why?
| | Awareness | 1 | 2010 | 41 | 0.130 |
Why?
| | Indicators and Reagents | 1 | 2010 | 20 | 0.130 |
Why?
| | Cardiac Output | 1 | 2010 | 19 | 0.130 |
Why?
| | Glomerulonephritis, Membranous | 1 | 2010 | 8 | 0.130 |
Why?
| | Consumer Product Safety | 1 | 2010 | 7 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2011 | 579 | 0.130 |
Why?
| | Drug Labeling | 1 | 2010 | 6 | 0.130 |
Why?
| | Ethanol | 1 | 2012 | 120 | 0.130 |
Why?
| | Immunohistochemistry | 1 | 2011 | 462 | 0.120 |
Why?
| | Health Care Reform | 1 | 2010 | 17 | 0.120 |
Why?
| | Erythrocytes | 1 | 2009 | 32 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2010 | 210 | 0.120 |
Why?
| | Developing Countries | 1 | 2009 | 26 | 0.120 |
Why?
| | Hematocrit | 1 | 2009 | 10 | 0.120 |
Why?
| | Global Health | 1 | 2009 | 51 | 0.120 |
Why?
| | Length of Stay | 2 | 2014 | 286 | 0.120 |
Why?
| | Sirolimus | 1 | 2009 | 16 | 0.120 |
Why?
| | Massachusetts | 1 | 2009 | 21 | 0.120 |
Why?
| | Ergocalciferols | 1 | 2009 | 2 | 0.120 |
Why?
| | Phosphorus | 1 | 2009 | 7 | 0.120 |
Why?
| | Calcitriol | 1 | 2009 | 6 | 0.120 |
Why?
| | Radioactive Tracers | 1 | 2008 | 2 | 0.120 |
Why?
| | Calcium | 2 | 2016 | 479 | 0.120 |
Why?
| | Tuberculosis, Osteoarticular | 1 | 2008 | 3 | 0.120 |
Why?
| | Diabetic Foot | 1 | 2008 | 4 | 0.120 |
Why?
| | Living Donors | 1 | 2009 | 17 | 0.120 |
Why?
| | Cilazapril | 1 | 2008 | 1 | 0.120 |
Why?
| | Glomerulonephritis, IGA | 1 | 2008 | 5 | 0.120 |
Why?
| | Orthopedic Fixation Devices | 1 | 2008 | 25 | 0.110 |
Why?
| | Ovarian Diseases | 1 | 2008 | 1 | 0.110 |
Why?
| | Publication Bias | 1 | 2008 | 6 | 0.110 |
Why?
| | Gadolinium | 1 | 2008 | 16 | 0.110 |
Why?
| | Kidney Diseases, Cystic | 1 | 2008 | 2 | 0.110 |
Why?
| | Radiography, Abdominal | 1 | 2008 | 6 | 0.110 |
Why?
| | Leuprolide | 1 | 2008 | 4 | 0.110 |
Why?
| | Menorrhagia | 1 | 2008 | 5 | 0.110 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 27 | 0.110 |
Why?
| | Puerperal Disorders | 1 | 2008 | 10 | 0.110 |
Why?
| | Reference Values | 2 | 2013 | 242 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 100 | 0.110 |
Why?
| | Probability | 1 | 2008 | 92 | 0.110 |
Why?
| | Renal Insufficiency | 1 | 2008 | 18 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2008 | 33 | 0.110 |
Why?
| | Polycythemia | 1 | 2008 | 1 | 0.110 |
Why?
| | Fournier Gangrene | 1 | 2008 | 2 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 292 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 19 | 0.110 |
Why?
| | Prednisone | 1 | 2008 | 70 | 0.110 |
Why?
| | Medicaid | 1 | 2008 | 35 | 0.110 |
Why?
| | Sclerosis | 1 | 2008 | 44 | 0.110 |
Why?
| | Iatrogenic Disease | 1 | 2008 | 18 | 0.110 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2008 | 12 | 0.110 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2008 | 15 | 0.110 |
Why?
| | Animals | 2 | 2009 | 4713 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2008 | 17 | 0.110 |
Why?
| | Nephrectomy | 1 | 2008 | 46 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2008 | 41 | 0.110 |
Why?
| | Odds Ratio | 1 | 2009 | 275 | 0.110 |
Why?
| | Metabolic Clearance Rate | 1 | 2007 | 8 | 0.110 |
Why?
| | Half-Life | 1 | 2007 | 16 | 0.110 |
Why?
| | Biological Availability | 1 | 2007 | 24 | 0.110 |
Why?
| | Primary Prevention | 1 | 2008 | 32 | 0.110 |
Why?
| | Periodicals as Topic | 1 | 2008 | 34 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 79 | 0.110 |
Why?
| | Clinical Competence | 1 | 2010 | 228 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2008 | 113 | 0.110 |
Why?
| | Graft Rejection | 1 | 2008 | 86 | 0.110 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 55 | 0.110 |
Why?
| | Hematopoiesis | 1 | 2007 | 14 | 0.100 |
Why?
| | Diffusion of Innovation | 1 | 2007 | 35 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 217 | 0.100 |
Why?
| | Pregnancy | 1 | 2008 | 320 | 0.100 |
Why?
| | Patient Dropouts | 1 | 2007 | 30 | 0.100 |
Why?
| | Bone Diseases | 1 | 2007 | 18 | 0.100 |
Why?
| | Tuberculosis | 1 | 2007 | 24 | 0.100 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 98 | 0.100 |
Why?
| | Confounding Factors (Epidemiology) | 1 | 2006 | 21 | 0.100 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 242 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 227 | 0.100 |
Why?
| | Morbidity | 1 | 2006 | 54 | 0.100 |
Why?
| | Fluoroscopy | 1 | 2006 | 41 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 366 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2013 | 320 | 0.100 |
Why?
| | Inpatients | 1 | 2008 | 100 | 0.100 |
Why?
| | Laparoscopy | 1 | 2008 | 158 | 0.090 |
Why?
| | Catheters, Indwelling | 1 | 2006 | 26 | 0.090 |
Why?
| | Graft Survival | 1 | 2006 | 106 | 0.090 |
Why?
| | Cadaver | 1 | 2006 | 305 | 0.090 |
Why?
| | Causality | 1 | 2005 | 48 | 0.090 |
Why?
| | Penis | 1 | 2005 | 49 | 0.090 |
Why?
| | Histology | 1 | 2004 | 4 | 0.090 |
Why?
| | Infusions, Intravenous | 1 | 2005 | 93 | 0.090 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 53 | 0.090 |
Why?
| | Patient Care Planning | 1 | 2005 | 51 | 0.090 |
Why?
| | Melena | 1 | 2004 | 1 | 0.090 |
Why?
| | Ovum | 1 | 2004 | 5 | 0.080 |
Why?
| | Spermatozoa | 1 | 2004 | 9 | 0.080 |
Why?
| | Mesenteric Artery, Superior | 1 | 2004 | 5 | 0.080 |
Why?
| | Oocytes | 1 | 2004 | 14 | 0.080 |
Why?
| | Embryo, Mammalian | 1 | 2004 | 34 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2012 | 894 | 0.080 |
Why?
| | Cryopreservation | 1 | 2004 | 20 | 0.080 |
Why?
| | Cell Transplantation | 1 | 2004 | 28 | 0.080 |
Why?
| | Nephrosis | 1 | 2003 | 5 | 0.080 |
Why?
| | Nephritis | 1 | 2003 | 3 | 0.080 |
Why?
| | Iothalamic Acid | 1 | 2003 | 2 | 0.080 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2003 | 3 | 0.080 |
Why?
| | Iodine Radioisotopes | 1 | 2003 | 24 | 0.080 |
Why?
| | Crohn Disease | 1 | 2004 | 42 | 0.080 |
Why?
| | Syndrome | 1 | 2003 | 101 | 0.080 |
Why?
| | Colitis, Ulcerative | 1 | 2004 | 70 | 0.080 |
Why?
| | Postoperative Period | 1 | 2003 | 170 | 0.070 |
Why?
| | Nucleosomes | 1 | 2002 | 4 | 0.070 |
Why?
| | Autoantibodies | 1 | 2002 | 94 | 0.070 |
Why?
| | Memory | 2 | 2014 | 305 | 0.070 |
Why?
| | Apoptosis | 1 | 2002 | 284 | 0.060 |
Why?
| | Myoglobinuria | 1 | 2019 | 2 | 0.060 |
Why?
| | Rhabdomyolysis | 1 | 2019 | 6 | 0.060 |
Why?
| | Carotid Artery, Internal | 1 | 2019 | 25 | 0.060 |
Why?
| | Magnetic Resonance Angiography | 1 | 2019 | 46 | 0.060 |
Why?
| | Muscle Weakness | 1 | 2019 | 34 | 0.060 |
Why?
| | Creatinine | 2 | 2009 | 53 | 0.060 |
Why?
| | Veins | 1 | 2017 | 7 | 0.050 |
Why?
| | Systole | 1 | 2017 | 22 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2014 | 1131 | 0.050 |
Why?
| | Therapeutic Equivalency | 1 | 2017 | 8 | 0.050 |
Why?
| | Hypotension | 1 | 2017 | 23 | 0.050 |
Why?
| | Arteries | 1 | 2017 | 20 | 0.050 |
Why?
| | Cerebral Infarction | 1 | 2019 | 142 | 0.050 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2017 | 28 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2017 | 48 | 0.050 |
Why?
| | Transferrin | 2 | 2008 | 6 | 0.050 |
Why?
| | Body Weight | 1 | 2017 | 145 | 0.050 |
Why?
| | Patient Acuity | 1 | 2016 | 9 | 0.050 |
Why?
| | Parathyroid Hormone | 1 | 2016 | 21 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2015 | 27 | 0.050 |
Why?
| | Cholesterol, HDL | 1 | 2015 | 27 | 0.040 |
Why?
| | Triglycerides | 1 | 2015 | 46 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2015 | 41 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2015 | 116 | 0.040 |
Why?
| | Image Enhancement | 1 | 2015 | 69 | 0.040 |
Why?
| | Oliguria | 1 | 2014 | 1 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2015 | 62 | 0.040 |
Why?
| | Burns, Chemical | 1 | 2014 | 3 | 0.040 |
Why?
| | Diuretics | 1 | 2014 | 13 | 0.040 |
Why?
| | Cause of Death | 1 | 2015 | 59 | 0.040 |
Why?
| | Sodium-Bicarbonate Symporters | 1 | 2014 | 1 | 0.040 |
Why?
| | Basal Ganglia Diseases | 1 | 2014 | 11 | 0.040 |
Why?
| | Homozygote | 1 | 2014 | 25 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2014 | 24 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 188 | 0.040 |
Why?
| | Mortality | 1 | 2014 | 61 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2014 | 85 | 0.040 |
Why?
| | Recurrence | 1 | 2014 | 327 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2013 | 22 | 0.040 |
Why?
| | Infant | 1 | 2014 | 569 | 0.040 |
Why?
| | Sepsis | 1 | 2014 | 139 | 0.040 |
Why?
| | Mental Status Schedule | 1 | 2013 | 123 | 0.040 |
Why?
| | Hemoglobinometry | 1 | 2012 | 1 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 35 | 0.040 |
Why?
| | Linear Models | 1 | 2013 | 255 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2012 | 357 | 0.030 |
Why?
| | Thailand | 1 | 2009 | 14 | 0.030 |
Why?
| | Logistic Models | 1 | 2011 | 437 | 0.030 |
Why?
| | Disease Management | 1 | 2009 | 110 | 0.030 |
Why?
| | Drug Interactions | 1 | 2008 | 66 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 1129 | 0.030 |
Why?
| | Health Expenditures | 1 | 2007 | 14 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2007 | 36 | 0.030 |
Why?
| | Equipment Failure | 1 | 2006 | 46 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2006 | 34 | 0.020 |
Why?
| | Demography | 1 | 2006 | 71 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2006 | 77 | 0.020 |
Why?
|
|
Singh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|